Index Pharma gets $20M for ulcerative colitis DNA drug
By Cormac Sheridan
Tuesday, February 25, 2014
With phase III data from ulcerative colitis DNA-based drug Kappaproct (DIMS0150) due in the coming months, Index Pharmaceuticals AB has added $20 million to its balance sheet in advance.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.